- ROUNDTABLE: Pharmacy’s future in sync with technology
- Senate passes Drug Quality and Security Act
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
PITTSBURGH — The Food and Drug Administration has approved a generic drug made by Mylan for cancer patients.
Mylan announced Monday the approval of dexrazoxane for injection, a generic version of Pharmacia & Upjohn's Zinecard. The drug is a chemoprotective agent, used to protect healthy tissue from cancer drugs.
Various versions of the drug had sales of $3.4 million during the 12-month period ended in September, according to IMS Health.